[K-Bio Big Data Awards] Antibody Therapeutics Development Speed 'Global Top'

Minister of Food and Drug Safety Award - Celltrion

[Asia Economy Reporter Cho Hyun-ui] The K-Bio Food and Drug Safety Minister's Award went to Celltrion, which is developing a domestic novel coronavirus disease (COVID-19) treatment. Celltrion is expected to complete the Phase 2 clinical trial of its COVID-19 antibody treatment 'CT-P59' as early as the end of this month. Antibody treatments gained attention as they were used for the treatment of U.S. President Donald Trump's COVID-19 infection. If CT-P59 receives emergency use authorization, it could be used in treatment settings by the end of the year.

Reflecting Celltrion's active role, major keywords in big data include 'clinical trial,' 'treatment,' 'COVID,' 'development,' and 'antibody.' This year, mentions of Celltrion have overwhelmingly focused on COVID-19 treatments. On March 12, when a mass infection occurred at a call center in Guro-gu, Seoul, Celltrion Chairman Seo Jung-jin made a surprise announcement, stating, "We will develop a COVID-19 treatment within six months." Subsequently, Celltrion secured candidate antibody treatment substances in just three weeks, a process that typically takes three to six months. After receiving approval for Phase 1 clinical trials in July, the company is currently conducting Phase 2 and 3 trials simultaneously.

Since last September, production of antibody treatments sufficient for 90,000 people has begun at a 12,500-liter production facility. To supply patients immediately after final approval, both pilot products and commercial products are being produced simultaneously. Early last month, the company accelerated patient recruitment by selecting the first test subjects.

Celltrion is regarded as the most advanced among global companies developing COVID-19 antibody treatments. Recently, multinational pharmaceutical companies Eli Lilly and Regeneron halted their COVID-19 antibody treatment clinical trials. However, the clinical trials for the antibody treatment developed by Celltrion are progressing smoothly. Celltrion is developing a monoclonal antibody treatment using the same method as Eli Lilly and Regeneron.

This content was produced with the assistance of AI translation services.